Top Markets
Coin of the day
Medivir AB (publ) Medivir AB (publ)

Medivir AB (publ)

MVIR-B
Rang in Aktien #29651
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Aktienkurs
$0.68377137
Zuletzt synchronisiert: 2023-05-23
Marktkapitalisierung
$20.23M
Veränderung (1 Tag)
-0.60%
Veränderung (1 Jahr)
0.00%
Land
SE
Handel Medivir AB (publ) (MVIR-B)

Kategorie

Dividendenhistorie für Medivir AB (publ) (MVIR-B)
Medivir AB (publ) (Aktienkürzel: MVIR-B) zahlte insgesamt 0 Dividenden.
Die Summe aller Dividenden (angepasst an Aktiensplits) beträgt: 0.00
Dividendenrendite (TTM): 0
Dividendenzahlungen für Medivir AB (publ) (MVIR-B) von 2026 bis 2026
Jährliche Dividendenzahlungen
Jahr Dividende (angepasst an Aktiensplits) ändert
Nicht genügend Daten für die angegebenen Daten.
Liste aller Dividendenzahlungen
Jahr Dividende ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenzahlungen ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Dividendenzahlungen Land
0.00%
US
0.00%
NL
64.00%
AU
0.00%
CH
0.00%
KR